Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2024; 16(5): 684-687
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.684
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.684
Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?
Howard D Lee, Li-Yun Yuan, Department of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, United States.
Author contributions: Lee HD and Yuan LY consulted and analyzed literature and wrote this manuscript; and both authors have read and approved of the final manuscript.
Conflict-of-interest statement: The authors have nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Howard D Lee, MD, Department of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, United States. howard.lee@med.usc.edu
Received: February 17, 2024
Revised: April 8, 2024
Accepted: April 15, 2024
Published online: May 27, 2024
Processing time: 95 Days and 10 Hours
Revised: April 8, 2024
Accepted: April 15, 2024
Published online: May 27, 2024
Processing time: 95 Days and 10 Hours
Core Tip
Core Tip: Despite recent advances in locoregional and systemic therapy for the treatment of hepatocellular carcinoma, current conventional treatment of advanced disease only offers limited survival benefit. Systemic therapy is particularly constrained by the inability for precise targeting of tumor cells, thus leading to systemic adverse effects and decreased efficacy in treatment. Nanotherapy holds the potential to overcome these traditional constraints but remains primarily a proof of concept at this juncture with in vivo studies in animal models. Further research and collaboration will ultimately lead to clinical applicability.